Groundbreaking Funding from PanKind Paves the Way for Pancreatic Cancer's First Early Detection Blood Test

A promising research project aimed at developing an early detection blood test for pancreatic cancer, one of the worlds deadliest, has successfully secured significant funding from PanKind, The Australian Pancreatic Cancer Foundation. This breakthrough could potentially revolutionize pancreatic cancer diagnosis, improving patient survival rates and quality of life.

The Need for a Novel Detection Method

Cancer Research UK state "There are around 10,500 new pancreatic cancer cases in the UK every year (2016-2018). Pancreatic cancer is the 10th most common cancer in the UK, accounting for 3% of all new cancer cases."
​​​

This statistic derives largely from the fact that the disease is often diagnosed late into its progression due to the absence of specific and recognizable early-stage symptoms. As a result, most diagnoses occur after the cancer has matured significantly, growing, and affecting nearby organs. An estimate of 10,500 people might succumb to this disease annually.

The lack of distinguishable symptoms and reliable screening tools in its early stages proves a significant challenge. Researchers believe that a blood-based test capable of identifying the disease at an early stage would be a crucial instrument towards enhancing survival rates.

The Potential of a Blood-Based Test

The project, led by renowned researcher and consultant medical oncologist Dr. Belinda Lee, proposes the blood-based test as a tool for early intervention, thereby providing better treatment options for patients. Currently, there are no early detection biomarkers for pancreatic cancer, a gap that the researchers are keen to fill.

According to Dr. Lee, the team has identified 13 proteins that hold the potential of distinguishing between early and late stages of pancreatic ductal adenocarcinoma (PDAC), the most prevalent type of pancreatic cancer. The intent, Dr. Lee explains, is to validate the functionality of these proteins in cancer screening. This breakthrough would provide medical professionals with the first diagnostic test for early-stage pancreatic cancer, a resource that is currently non-existent.

Methodology and Expectation

In their quest, the researchers will depend heavily on the global PURPLE Pancreatic Cancer Translational Registry database, started by Dr. Lee in 2016. The database, supported by philanthropic funding, played a vital role in the identification of the 13 crucial proteins. The registry acts as a massive catalogue of the treatment journey of patients from 48 cancer centres across Australia, New Zealand, and Singapore. With data gathered from over 4000 patients and 2000 biospecimens, it's an invaluable resource.

Applying state-of-the-art technologies and computational methodologies, the team will compare the protein signature in the blood of healthy individuals with pancreatic cancer patients at both early and late-stage disease. The project's fundamental goal is to develop a simple, non-invasive screening test that can identify early-stage pancreatic cancer. The vision is that this tool will not only help general practitioners but also oncologists, aiding in a quicker diagnosis of this silent cancer, which could result in increased patient remission rates and a potential tripling of survival rates by 2030.

Sustained Support and Next Steps

The research project titled, 'Development of a blood-based test to identify patients with early pancreatic cancer,' received a grant of $100,000 from the Marianne Allan Pancreatic Cancer Research Grant, demonstrating PanKind's commitment to advanced pancreatic cancer research.

While the journey towards an actionable early-detection test for pancreatic cancer remains an uphill task, these concerted efforts signal hope, reaffirming the commitment to eliminate one of the deadliest cancers.